EFPIA objects to ‘pressure’ from EMA over theoretical medicines shortages
This article was originally published in Scrip
EFPIA, the federation of R&D-based industry associations, is using concern about the impact of forthcoming legislation on drug shortages to call for the European Medicines Agency to look more closely the impact of low prices. EFPIA is warning the agency that it must find a pragmatic way to implement the highly problematic Falsified Medicines Directive.
You may also be interested in...
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.